Figure 6.

Heat map of treatment suppression of pathways activated by infection. Functional grouping that compares amounts of treatment suppression of canonical pathways that were activated during Mycoplasma pulmonis infection (7 days) (condition A). The infected group treated with vehicle has the highest values (purple-blue), and the pathogen-free group has the lowest values (pink). Pathways, assessed by Ingenuity Pathway Analysis, are the same as shown in Table 4. The three treatment columns show relative efficacy, color coded as the difference between log10 of P value for the infected vehicle group and log10 of P value for the corresponding treatment. Treatment efficacy is reflected in the shift from purple-blue toward pink, where lighter colors indicate smaller differences from the pathogen-free baseline. Each step from purple-blue to pink indicates a 10^2.5-fold change in the P value for the treatment-related suppression of pathway activity. For all but two of these pathways (asterisks), the antibody combination reduced the activity closer to the baseline than the other treatments. P values calculated by Fisher's exact text are corrected for false positives by using the Benjamini-Hochberg procedure. Ang2, angiopoietin-2; fMLP, N-formyl-Met-Leu-Phe; iNOS, inducible NO synthase; MAPK, mitogen-activated protein kinase; NO, nitric oxide; PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species; TNF, tumor necrosis factor; TNFR, TNF receptor; TNFSF, TNF superfamily.